Lowest Price Guaranteed
Pages
351
Last Updated
August 2026
View Count
5771
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russia-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID-19 Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Rapid Sterility Testing for Cell and Gene Therapies: Market Landscape
5.2. Rapid Sterility Testing for Cell and Gene Therapies: Market Trends
5.3. Rapid Sterility Testing for Cell and Gene Therapies: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Sterility Testing
6.2.1. The Need for Sterility Testing in Cell and Gene Therapy Manufacturing
6.2.2. Comparison of Compendial and Rapid Sterility Testing
6.2.3. Validation of Rapid Sterility Testing Methods
6.3. Classification of Rapid Sterility Testing Methods
6.3.1. Growth-based Methods
6.3.2. Nucleic Acid-based Methods
6.3.3. Cellular Component-based Methods
6.3.4. Viability-based Methods
6.3.5. Microfluidic Methods
6.3.6. Other Methods
6.4. Key Applications of Rapid Sterility Testing in Cell and Gene Therapies
6.4.1. Raw Material Testing
6.4.2. In-process Testing
6.4.3. Final Product Release Testing
6.4.4. Environmental Monitoring
6.5. Advantages of Rapid Sterility Testing Implementation
6.6. Challenges and Barriers to Rapid Sterility Testing Adoption
6.7. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Rapid Sterility Testing Solution Providers for Cell and Gene Therapies: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Company Ownership
7.2.5. Analysis by Type of Offering
7.2.6. Analysis by Type of Instrument
7.2.7. Analysis by Method of Testing
7.2.8. Analysis by Mode of Testing
7.2.9. Analysis by Type of Pathogen
7.2.10. Analysis by End User
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Rapid Sterility Testing Solution Providers for Cell and Gene Therapies: Company Competitiveness Analysis
8.4.1. Established Players (Peer Group I)
8.4.2. Emerging Players (Peer Group II)
9. COMPANY PROFILES: RAPID STERILITY TESTING SOLUTION PROVIDERS FOR CELL AND GENE THERAPIES
9.1. Chapter Overview
9.2. Established Rapid Sterility Testing Solution Providers
9.2.1. Becton, Dickinson and Company
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Product Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.2.2. bioMérieux
9.2.2.1. Company Overview
9.2.2.2. Financial Information
9.2.2.3. Product Portfolio
9.2.2.4. Recent Developments and Future Outlook
9.2.3. Charles River Laboratories
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Product Portfolio
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Rapid Micro Biosystems
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. Product Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.2.5. Sartorius
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Product Portfolio
9.2.5.4. Recent Developments and Future Outlook
9.2.6. Thermo Fisher Scientific
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. Product Portfolio
9.2.6.4. Recent Developments and Future Outlook
9.3. Emerging Rapid Sterility Testing Solution Providers
9.3.1. biotactical
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Recent Developments and Future Outlook
9.3.2. IntuBio
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Recent Developments and Future Outlook
9.3.3. Mango
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Recent Developments and Future Outlook
9.3.4. Microbs
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Recent Developments and Future Outlook
9.3.5. Symcel
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Recent Developments and Future Outlook
10. RECENT DEVELOPMENTS
10.1. Chapter Overview
10.2. Partnerships and Collaborations
10.2.1. Partnership Models
10.2.2. Rapid Sterility Testing Solution Providers for Cell and Gene Therapies: Partnerships and Collaborations
10.2.3. Analysis by Year of Partnership
10.2.4. Analysis by Type of Partnership
10.2.5. Analysis by Year and Type of Partnership
10.2.6. Most Active Players: Analysis by Number of Partnerships
10.2.7. Analysis by Geography
10.2.7.1. Intercontinental and Intracontinental Agreements
10.2.7.2. Local and International Agreements
10.3. Funding and Investment Analysis
10.3.1. Funding Models
10.3.2. List of Funding and Investments
10.3.3. Analysis by Year of Funding
10.3.3.1. Cumulative Year-wise Trend of Funding Instances
10.3.3.2. Cumulative Year-wise Trend of Amount Invested
10.3.4. Analysis by Type of Funding
10.3.4.1. Analysis of Funding Instances
10.3.4.2. Analysis of Amount Invested
10.3.5. Analysis by Geography
10.3.6. Most Active Players: Analysis by Number of Funding Instances
10.3.7. Most Active Players: Analysis by Amount Raised
11. PORTER’S FIVE FORCES ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Assumptions
11.3. Key Elements of Porter’s Five Forces
11.3.1. Threat of New Entrants
11.3.2. Bargaining Power of Buyers
11.3.3. Bargaining Power of Solution Providers
11.3.4. Threats of Substitute Products
11.3.5. Rivalry Among Existing Competitors
11.4. Conclusion
12. VENDOR SELECTION FRAMEWORK
12.1. Chapter Overview
12.2. Methodology
12.3. Key Parameters
12.4. Value Addition vs Evaluation Complexity Matrix
12.5. Benchmarking of Parameters
12.6. Case Study Assessment of Rapid Micro Biosystems
12.7. Overview of Vendor Assessment Dashboard
12.7.1. Vendor Selection Framework: Dashboard (Scenario I)
12.7.2. Vendor Selection Framework: Dashboard (Scenario II)
12.7.3. Vendor Selection Framework: Dashboard (Scenario III)
12.8. Concluding Remarks
13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion
14. GLOBAL RAPID STERILITY TESTING FOR CELL AND GENE THERAPIES MARKET
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Rapid Sterility Testing for Cell and Gene Therapies Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
14.3.1. Scenario Analysis
14.3.1.1. Conservative Scenario
14.3.1.2. Optimistic Scenario
14.4. Key Market Segmentations
15. RAPID STERILITY TESTING FOR CELL AND GENE THERAPIES MARKET, BY TYPE OF OFFERING
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Rapid Sterility Testing for Cell and Gene Therapies Market: Distribution by Type of Offering
15.3.1. Rapid Sterility Testing for Cell and Gene Therapies Market for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.3.2. Rapid Sterility Testing for Cell and Gene Therapies Market for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.3.3. Rapid Sterility Testing for Cell and Gene Therapies Market for Software and Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.4. Data Triangulation and Validation
16. RAPID STERILITY TESTING INSTRUMENTS MARKET FOR CELL AND GENE THERAPIES, BY TYPE OF INSTRUMENT
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Rapid Sterility Testing Instruments Market for Cell and Gene Therapies: Distribution by Type of Instrument
16.3.1. Rapid Sterility Testing Instruments Market for Cell and Gene Therapies for Automated Detection Systems, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.3.2. Rapid Sterility Testing Instruments Market for Cell and Gene Therapies for PCR Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.3.3. Rapid Sterility Testing Instruments Market for Cell and Gene Therapies for Luminometers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.3.4. Rapid Sterility Testing Instruments Market for Cell and Gene Therapies for Solid Phase Cytometers / Flow Cytometers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.3.5. Rapid Sterility Testing Instruments Market for Cell and Gene Therapies for Other Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.4. Data Triangulation and Validation
17. RAPID STERILITY TESTING FOR CELL AND GENE THERAPIES MARKET, BY METHOD OF TESTING
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Rapid Sterility Testing for Cell and Gene Therapies Market: Distribution by Method of Testing
17.3.1. Rapid Sterility Testing for Cell and Gene Therapies Market for Growth-based Methods, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.2. Rapid Sterility Testing for Cell and Gene Therapies Market for Nucleic Acid-based Methods, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.3. Rapid Sterility Testing for Cell and Gene Therapies Market for Cellular Component-based Methods, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.4. Rapid Sterility Testing for Cell and Gene Therapies Market for Viability-based Methods, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.5. Rapid Sterility Testing for Cell and Gene Therapies Market for Microfluidic Methods, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.6. Rapid Sterility Testing for Cell and Gene Therapies Market for Other Methods, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation
18. RAPID STERILITY TESTING FOR CELL AND GENE THERAPIES MARKET, BY TYPE OF PATHOGEN
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Rapid Sterility Testing for Cell and Gene Therapies Market: Distribution by Type of Pathogen
18.3.1. Rapid Sterility Testing for Cell and Gene Therapies Market for Bacteria, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.2. Rapid Sterility Testing for Cell and Gene Therapies Market for Fungi, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19. RAPID STERILITY TESTING FOR CELL AND GENE THERAPIES MARKET, BY END USER
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Rapid Sterility Testing for Cell and Gene Therapies Market: Distribution by End User
19.3.1. Rapid Sterility Testing for Cell and Gene Therapies Market for Drug Developers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.2. Rapid Sterility Testing for Cell and Gene Therapies Market for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20. RAPID STERILITY TESTING FOR CELL AND GENE THERAPIES MARKET, BY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Rapid Sterility Testing for Cell and Gene Therapies Market: Distribution by Geographical Regions
20.3.1. Rapid Sterility Testing for Cell and Gene Therapies Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.2. Rapid Sterility Testing for Cell and Gene Therapies Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.3. Rapid Sterility Testing for Cell and Gene Therapies Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.4. Rapid Sterility Testing for Cell and Gene Therapies Market in Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.5. Rapid Sterility Testing for Cell and Gene Therapies Market in Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.4. Market Dynamics Assessment
20.4.1. Market Movement Analysis
20.4.2. Penetration Growth (P-G) Matrix
20.5. Data Triangulation and Validation
21. CONCLUDING REMARKS
22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Company A
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Founder and Managing Director
22.3. Company B
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Chief Operating Officer and Chief Financial Officer
22.4. Company C
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Senior Vice President of Sales
22.5. Company D
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Head of Business Development
22.6. Company E
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Technical Sales and Marketing Coordinator
22.7. Company F
22.7.1. Company Snapshot
22.7.2. Interview Transcript: Founder and Chief Operating Officer
22.8. Company G
22.8.1. Company Snapshot
22.8.2. Interview Transcript: Vice President, Quality and Compliance
22.9. Company H
22.9.1. Company Snapshot
22.9.2. Interview Transcript: Vice President of Analytical Sciences and Former Marketing Manager
22.10. Company I
22.10.1. Company Snapshot
22.10.2. Interview Transcript: Former Scientific Director and Vice President Sales and Marketing
22.11. Company J
22.11.1. Company Snapshot
22.11.2. Interview Transcript: Senior Director, Manufacturing Operations
22.12. Company K
22.12.1. Company Snapshot
22.12.2. Interview Transcript: Global Sales Director, Pharma Analytics
22.13. Company L
22.13.1. Company Snapshot
22.13.2. Interview Transcript: Global Segment Director
22.14. Company M
22.14.1. Company Snapshot
22.14.2. Interview Transcript: Pharmaceutical Affairs Director
22.15. Company N
22.15.1. Company Snapshot
22.15.2. Interview Transcript: Former Director of Product Design and Development
22.16. Company O
22.16.1. Company Snapshot
22.16.2. Interview Transcript: Senior Technology Specialist and Microbiology Technology Specialist
22.17. Company P
22.17.1. Company Snapshot
22.17.2. Interview Transcript: Field Technology Specialist
23. APPENDIX I: TABULATED DATA
24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS